Further to its bulletin dated March 18, 2026, the Toronto Stock Exchange reports that it has extended its review of the eligibility of the common shares of Aptose Biosciences Inc. for continued listing for a period of 30 days.
© 2026 Canjex Publishing Ltd. All rights reserved.